CN201701512U - 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 - Google Patents
装有氯雷他定片和盐酸氨溴索片的片剂胶囊 Download PDFInfo
- Publication number
- CN201701512U CN201701512U CN2010202421680U CN201020242168U CN201701512U CN 201701512 U CN201701512 U CN 201701512U CN 2010202421680 U CN2010202421680 U CN 2010202421680U CN 201020242168 U CN201020242168 U CN 201020242168U CN 201701512 U CN201701512 U CN 201701512U
- Authority
- CN
- China
- Prior art keywords
- capsule
- tablets
- tablet
- loratadine
- ambroxol hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 67
- 229960003088 loratadine Drugs 0.000 title claims abstract description 35
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title claims abstract description 35
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 28
- 239000003086 colorant Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 abstract description 16
- 239000000047 product Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 3
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 description 12
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940080781 loratadine 5 mg Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- -1 amino 3.5-dibromo-benzyl Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
实施例1 | ||
0天含量 | 氨溴索(%) | 99.28 |
氯雷他定(%) | 99.14 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.02 | |
5天含量 | 氨溴索(%) | 99.46 |
氯雷他定(%) | 99.17 | |
5天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.02 | |
10天含量 | 氨溴索(%) | 99.33 |
氯雷他定(%) | 99.57 | |
10天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.04 |
实施例1 | ||
0天含量 | 氨溴索(%) | 99.28 |
氯雷他定(%) | 99.14 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.02 |
5天含量 | 氨溴索(%) | 99.43 |
氯雷他定(%) | 99.15 | |
5天有关物质 | N-A873CL | 0.01 |
N-AB773XX | 0.02 | |
10天含量 | 氨溴索(%) | 99.35 |
氯雷他定(%) | 99.58 | |
10天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.02 |
实施例1 | ||
0天含量 | 氨溴索(%) | 99.28 |
氯雷他定(%) | 99.14 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.02 | |
5天含量 | 氨溴索(%) | 99.42 |
氯雷他定(%) | 99.13 | |
5天有关物质 | N-A873CL | 0.01 |
N-AB773XX | 0.03 | |
10天含量 | 氨溴索(%) | 99.37 |
氯雷他定(%) | 99.59 | |
10天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.03 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010202421680U CN201701512U (zh) | 2010-06-30 | 2010-06-30 | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010202421680U CN201701512U (zh) | 2010-06-30 | 2010-06-30 | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN201701512U true CN201701512U (zh) | 2011-01-12 |
Family
ID=43438655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010202421680U Expired - Fee Related CN201701512U (zh) | 2010-06-30 | 2010-06-30 | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN201701512U (zh) |
-
2010
- 2010-06-30 CN CN2010202421680U patent/CN201701512U/zh not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104382878A (zh) | 一种盐酸氟桂利嗪胶囊及其制备方法 | |
CN201701512U (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN201701513U (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN102266343A (zh) | 供注射用盐酸法舒地尔药物组合物 | |
CN102018694A (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 | |
CN201701514U (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN102018709A (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN104447770A (zh) | 阿塞那平化合物 | |
CN201701510U (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 | |
CN102008478A (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN201701511U (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN202568930U (zh) | 装有瑞格列奈固体制剂和二甲双胍固体制剂的片剂胶囊 | |
CN102018719A (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN202146449U (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 | |
CN201834922U (zh) | 真菌药敏检测板 | |
CN102274231A (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 | |
CN202568926U (zh) | 装有阿格列汀固体制剂和吡格列酮固体制剂的片剂胶囊 | |
CN202568927U (zh) | 装有罗氟司特固体制剂和福莫特罗固体制剂的新型胶囊 | |
CN102008467A (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN202568929U (zh) | 装有罗格列酮固体制剂和二甲双胍固体制剂的片剂胶囊 | |
CN202568932U (zh) | 装有厄贝沙坦固体制剂和氢氯噻嗪固体制剂的新型胶囊 | |
Khattry et al. | Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy | |
CN103356621A (zh) | 装有阿格列汀固体制剂和吡格列酮固体制剂的新型胶囊 | |
CN103356615A (zh) | 装有瑞格列奈片和二甲双胍片的片剂胶囊 | |
CN202620280U (zh) | 装有培哚普利固体制剂和吲达帕胺固体制剂的新型胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG FUHE HUAXING PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: WU GUANGYAN Effective date: 20110518 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 151100 HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO., LTD., NO. 34, TAIPING ROAD, ZHAODONG CITY, SUIHUA CITY, HEILONGJIANG PROVINCE TO: 151100 HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO., LTD., NO. 34, TAIPING ROAD, ZHAODONG CITY, HEILONGJIANG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110518 Address after: 151100 Heilongjiang Zhaodong Taiping Road 34, Heilongjiang Dilong pharmaceutical Limited by Share Ltd Patentee after: Heilongjiang Fuhe Huaxing Pharmaceutical Group Co., Ltd. Address before: 151100 Suihua City, Heilongjiang province Zhaodong City, Taiping Road, No. 34 Heilongjiang Dilong pharmaceutical Limited by Share Ltd Patentee before: Wu Guangyan |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110112 Termination date: 20170630 |